Disc Medicine surges on positive FDA feedback for genetic disorder drug

Disc Medicine

04/11/2024 15:03

** Shares of drug developer Disc Medicine  IRON.O  rise
~28.6% to $60.60, highest since March
    ** Co says the FDA gave positive feedback supporting the
design of a trial that will evaluate its genetic disorder drug
bitopertin
    ** Bitopertin is being developed for the treatment of
Erythropoietic protoporphyria (EPP), a rare inherited metabolic
disorder
    ** IRON says the drug has potential for FDA's accelerated
approval based on existing data
    ** "Improved approval timelines and clarification of
confirmatory trial design are significant positives to IRON
shares," says BMO Capital Markets
    ** Stock up 15.1% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))